Glenmark Pharmaceuticals Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: February 27, 2025, 2:43 pm

Market Cap	36,826 Cr.
Current Price	1,305
High / Low	1,831/883
Stock P/E
Book Value	299
Dividend Yield	0.19 %
ROCE	12.3 %
ROE	50.9 %
Face Value	1.00
PEG Ratio	0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Glenmark Pharmaceuticals Ltd

Competitors of Glenmark Pharmaceuticals Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.42 Cr.	3.88	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	52.6 Cr.	70.9	94.9/30.9	17.8	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	40.0 Cr.	27.3	29.0/8.74	40.8	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	65.6 Cr.	87.1	155/81.2	10.6	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	16,732.40 Cr	1,046.67		41.61	185.19	0.37%	16.18%	16.43%	6.27

All Competitor Stocks of Glenmark Pharmaceuticals Ltd

Quarterly Result

Metric	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Sales	2,965	3,147	3,173	3,019	2,777	3,018	3,100	3,001	3,036	3,207	2,507	3,063	3,244
Expenses	2,391	2,557	2,480	2,556	2,346	2,539	2,626	2,603	2,599	2,745	2,715	2,559	2,656
Operating Profit	574	590	693	463	432	479	474	398	437	462	-209	504	588
OPM %	19%	19%	22%	15%	16%	16%	15%	13%	14%	14%	-8%	16%	18%
Other Income	59	-13	-164	25	183	86	209	-696	-32	-205	87	351	31
Interest	76	69	67	87	60	83	97	109	112	121	134	149	40
Depreciation	113	123	119	132	147	146	152	135	142	141	147	151	118
Profit before tax	444	385	343	270	408	337	435	-542	151	-6	-403	555	462
Tax %	31%	29%	30%	36%	48%	17%	33%	-26%	-14%	997%	-18%	319%	26%
Net Profit	307	275	240	173	211	279	291	-403	173	-62	-331	-1,214	340
EPS in Rs	10.86	9.13	7.86	5.51	6.82	9.23	9.66	-15.18	5.31	-2.90	-12.45	-43.17	12.06

Last Updated: Unknown

Below is a detailed analysis of the quarterly data for Glenmark Pharmaceuticals Ltd based on the most recent figures (Jun 2024) and their trends compared to the previous period:

For Sales, as of Jun 2024, the value is ₹3,244.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹3,063.00 Cr. (Mar 2024) to ₹3,244.00 Cr., marking an increase of ₹181.00 Cr..
For Expenses, as of Jun 2024, the value is ₹2,656.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹2,559.00 Cr. (Mar 2024) to ₹2,656.00 Cr., marking an increase of ₹97.00 Cr..
For Operating Profit, as of Jun 2024, the value is ₹588.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹504.00 Cr. (Mar 2024) to ₹588.00 Cr., marking an increase of ₹84.00 Cr..
For OPM %, as of Jun 2024, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Mar 2024) to 18.00%, marking an increase of 2.00%.
For Other Income, as of Jun 2024, the value is ₹31.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹351.00 Cr. (Mar 2024) to ₹31.00 Cr., marking a decrease of ₹320.00 Cr..
For Interest, as of Jun 2024, the value is ₹40.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from ₹149.00 Cr. (Mar 2024) to ₹40.00 Cr., marking a decrease of ₹109.00 Cr..
For Depreciation, as of Jun 2024, the value is ₹118.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from ₹151.00 Cr. (Mar 2024) to ₹118.00 Cr., marking a decrease of ₹33.00 Cr..
For Profit before tax, as of Jun 2024, the value is ₹462.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹555.00 Cr. (Mar 2024) to ₹462.00 Cr., marking a decrease of ₹93.00 Cr..
For Tax %, as of Jun 2024, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 319.00% (Mar 2024) to 26.00%, marking a decrease of 293.00%.
For Net Profit, as of Jun 2024, the value is ₹340.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹-1,214.00 Cr. (Mar 2024) to ₹340.00 Cr., marking an increase of ₹1,554.00 Cr..
For EPS in Rs, as of Jun 2024, the value is ₹12.06. The value appears strong and on an upward trend. It has increased from ₹-43.17 (Mar 2024) to ₹12.06, marking an increase of ₹55.23.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	5,012	6,005	6,563	7,562	9,079	9,074	9,865	10,641	10,944	12,305	12,990	11,813	12,021
Expenses	3,997	4,914	5,348	6,125	7,043	7,457	8,280	8,942	8,860	9,978	10,712	10,618	10,675
Operating Profit	1,015	1,091	1,214	1,437	2,037	1,617	1,586	1,699	2,084	2,327	2,278	1,195	1,346
OPM %	20%	18%	18%	19%	22%	18%	16%	16%	19%	19%	18%	10%	11%
Other Income	11	11	-180	20	-44	89	375	191	95	-101	-449	336	265
Interest	160	189	190	179	237	286	335	377	353	298	350	516	444
Depreciation	127	217	300	234	264	302	326	417	444	487	611	582	558
Profit before tax	739	697	544	1,044	1,491	1,119	1,301	1,096	1,382	1,441	868	434	609
Tax %	15%	22%	61%	29%	26%	28%	29%	29%	30%	31%	57%	430%
Net Profit	628	546	209	743	1,109	804	925	776	970	994	377	-1,434	-1,266
EPS in Rs	22.89	19.99	7.72	26.33	39.29	28.49	32.78	27.50	34.38	33.37	10.53	-53.22	-46.46
Dividend Payout %	0%	0%	26%	8%	5%	7%	6%	9%	7%	7%	24%	-5%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-13.06%	-61.72%	255.50%	49.26%	-27.50%	15.05%	-16.11%	25.00%	2.47%	-62.07%	-480.37%
Change in YoY Net Profit Growth (%)	0.00%	-48.66%	317.22%	-206.24%	-76.76%	42.55%	-31.16%	41.11%	-22.53%	-64.55%	-418.30%

Glenmark Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	7%
5 Years:	4%
3 Years:	3%
TTM:	12%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-5102%

Stock Price CAGR
10 Years:	5%
5 Years:	36%
3 Years:	43%
1 Year:	44%

Return on Equity
10 Years:	5%
5 Years:	-3%
3 Years:	-11%
Last Year:	-51%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:35 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	27	27	27	28	28	28	28	28	28	28	28	28	28
Reserves	2,736	2,956	1,756	3,601	4,464	5,135	5,577	6,042	7,036	9,058	9,446	7,820	8,417
Borrowings	2,765	3,267	3,800	3,988	4,724	4,639	4,449	4,869	4,986	3,962	4,608	1,231	1,711
Other Liabilities	1,466	2,176	2,726	2,575	2,548	2,793	3,235	3,729	3,524	4,003	5,289	5,279	5,009
Total Liabilities	6,994	8,427	8,309	10,193	11,764	12,595	13,289	14,668	15,575	17,052	19,371	14,358	15,165
Fixed Assets	2,822	3,091	2,015	2,594	2,755	3,030	3,670	5,029	5,129	5,887	5,422	4,210	4,507
CWIP	6	5	477	543	708	1,122	1,399	1,222	1,382	1,010	1,190	662	395
Investments	0	0	17	17	16	15	30	25	25	50	45	790	45
Other Assets	4,166	5,331	5,799	7,039	8,285	8,429	8,190	8,393	9,040	10,105	12,715	8,697	10,219
Total Assets	6,994	8,427	8,309	10,193	11,764	12,595	13,289	14,668	15,575	17,052	19,371	14,358	15,165

Below is a detailed analysis of the balance sheet data for Glenmark Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹28.00 Cr..
For Reserves, as of Sep 2024, the value is ₹8,417.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹7,820.00 Cr. (Mar 2024) to ₹8,417.00 Cr., marking an increase of ₹597.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹1,711.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹1,231.00 Cr. (Mar 2024) to ₹1,711.00 Cr., marking an increase of ₹480.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹5,009.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹5,279.00 Cr. (Mar 2024) to ₹5,009.00 Cr., marking a decrease of ₹270.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹15,165.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹14,358.00 Cr. (Mar 2024) to ₹15,165.00 Cr., marking an increase of ₹807.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹4,507.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹4,210.00 Cr. (Mar 2024) to ₹4,507.00 Cr., marking an increase of ₹297.00 Cr..
For CWIP, as of Sep 2024, the value is ₹395.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹662.00 Cr. (Mar 2024) to ₹395.00 Cr., marking a decrease of ₹267.00 Cr..
For Investments, as of Sep 2024, the value is ₹45.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹790.00 Cr. (Mar 2024) to ₹45.00 Cr., marking a decrease of ₹745.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹10,219.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹8,697.00 Cr. (Mar 2024) to ₹10,219.00 Cr., marking an increase of ₹1,522.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹15,165.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹14,358.00 Cr. (Mar 2024) to ₹15,165.00 Cr., marking an increase of ₹807.00 Cr..

Notably, the Reserves (₹8,417.00 Cr.) exceed the Borrowings (₹1,711.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	648	854	482	345	657	1,648	1,324	1,392	1,131	1,109	625	-265
Cash from Investing Activity +	-558	-566	-712	-950	-1,001	-1,003	-883	-774	-662	-316	-515	4,387
Cash from Financing Activity +	195	-98	199	699	543	-468	-739	-445	-442	-520	-77	-3,906
Net Cash Flow	285	190	-31	93	199	177	-297	174	28	272	32	215

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-1.00	-2.00	-2.00	-2.00	-2.00	-3.00	-3.00	-3.00	-2.00	-1.00	-2.00	0.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	119	131	140	120	97	94	81	83	86	92	115	57
Inventory Days	194	191	247	249	299	244	244	211	230	208	203	208
Days Payable	239	279	379	308	243	225	241	210	226	190	172	210
Cash Conversion Cycle	75	43	8	61	152	113	85	84	90	110	147	56
Working Capital Days	94	83	66	89	133	111	76	69	96	100	159	32
ROCE %	18%	15%	16%	19%	21%	15%	15%	14%	15%	16%	10%	12%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%
FIIs	24.12%	24.23%	23.14%	23.19%	22.47%	25.51%	24.79%	23.71%	21.38%	20.98%	23.05%	23.51%
DIIs	10.96%	10.50%	10.90%	10.69%	10.40%	9.10%	10.31%	10.92%	13.36%	13.93%	13.21%	13.85%
Government	0.00%	0.00%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%
Public	18.27%	18.63%	19.27%	19.45%	20.46%	18.70%	18.21%	18.70%	18.58%	18.42%	17.06%	15.96%
No. of Shareholders	3,10,516	3,12,473	3,13,540	3,00,106	2,85,461	2,36,908	2,32,685	2,09,931	1,99,451	1,92,630	1,93,949	1,95,059

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Aditya Birla Sun Life Flexi Cap Fund	2,000,000	1.29	293.75	463,185	2025-02-26	331.79%
Aditya Birla Sun Life Midcap Fund	1,135,697	2.74	166.81	463,185	2025-02-26	145.19%
UTI Value Fund	950,000	1.35	139.53	463,185	2025-02-26	105.1%
Mahindra Manulife Small Cap Fund	700,000	2.04	102.81	463,185	2025-02-26	51.13%
Bandhan Core Equity Fund	550,000	1.35	80.78	463,185	2025-02-26	18.74%
Kotak Equity Arbitrage Fund - Regular Plan	479,950	0.14	70.49	463,185	2025-02-26	3.62%
Bandhan Small Cap Fund	463,185	1.02	68.03	463,185	2025-02-26	0%
UTI Large & Mid Cap Fund	341,900	1.34	50.22	463,185	2025-02-26	-26.19%
Bandhan Flexi Cap Fund	325,000	0.62	47.73	463,185	2025-02-26	-29.83%
HDFC Large and Mid Cap Fund - Regular Plan	311,000	0.2	45.68	463,185	2025-02-26	-32.86%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	-53.22	10.53	33.37	34.38	27.50
Diluted EPS (Rs.)	-53.22	10.53	33.37	34.38	27.50
Cash EPS (Rs.)	-30.18	35.04	52.46	50.10	42.28
Book Value[Excl.RevalReserv]/Share (Rs.)	278.09	348.70	334.48	250.36	215.12
Book Value[Incl.RevalReserv]/Share (Rs.)	278.09	348.70	334.48	250.36	215.12
Revenue From Operations / Share (Rs.)	418.62	460.36	436.08	387.85	377.11
PBDIT / Share (Rs.)	72.13	91.97	88.14	75.65	65.84
PBIT / Share (Rs.)	51.50	70.31	70.89	59.93	51.05
PBT / Share (Rs.)	1.29	30.78	51.08	48.99	38.84
Net Profit / Share (Rs.)	-50.80	13.37	35.21	34.38	27.50
NP After MI And SOA / Share (Rs.)	-53.21	10.53	33.37	34.38	27.50
PBDIT Margin (%)	17.22	19.97	20.21	19.50	17.45
PBIT Margin (%)	12.30	15.27	16.25	15.45	13.53
PBT Margin (%)	0.30	6.68	11.71	12.63	10.30
Net Profit Margin (%)	-12.13	2.90	8.07	8.86	7.29
NP After MI And SOA Margin (%)	-12.71	2.28	7.65	8.86	7.29
Return on Networth / Equity (%)	-19.13	3.13	10.36	13.73	12.78
Return on Capital Employeed (%)	17.01	13.84	16.13	14.83	13.64
Return On Assets (%)	-10.45	1.53	5.51	6.21	5.28
Long Term Debt / Equity (X)	0.00	0.40	0.28	0.55	0.66
Total Debt / Equity (X)	0.12	0.45	0.40	0.66	0.73
Asset Turnover Ratio (%)	0.70	0.71	0.42	0.42	0.41
Current Ratio (X)	1.28	1.96	1.77	1.75	1.65
Quick Ratio (X)	0.84	1.37	1.23	1.21	1.13
Inventory Turnover Ratio (X)	1.15	1.31	1.85	1.85	1.46
Dividend Payout Ratio (NP) (%)	-4.69	23.73	7.49	7.27	8.76
Dividend Payout Ratio (CP) (%)	-7.66	7.76	4.93	4.99	5.70
Earning Retention Ratio (%)	104.69	76.27	92.51	92.73	91.24
Cash Earning Retention Ratio (%)	107.66	92.24	95.07	95.01	94.30
Interest Coverage Ratio (X)	3.94	7.42	8.34	6.04	4.92
Interest Coverage Ratio (Post Tax) (X)	-0.80	4.27	5.21	3.62	2.97
Enterprise Value (Cr.)	26350.45	16364.27	15087.86	16656.12	9188.07
EV / Net Operating Revenue (X)	2.23	1.26	1.23	1.52	0.86
EV / EBITDA (X)	12.95	6.31	6.07	7.80	4.95
MarketCap / Net Operating Revenue (X)	2.29	1.01	1.01	1.20	0.54
Retention Ratios (%)	104.69	76.26	92.50	92.72	91.23
Price / BV (X)	3.44	1.38	1.37	1.86	0.95
Price / Net Operating Revenue (X)	2.29	1.01	1.01	1.20	0.54
EarningsYield	-0.05	0.02	0.07	0.07	0.13

After reviewing the key financial ratios for Glenmark Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 24, the value is -53.22. This value is below the healthy minimum of 5. It has decreased from 10.53 (Mar 23) to -53.22, marking a decrease of 63.75.
For Diluted EPS (Rs.), as of Mar 24, the value is -53.22. This value is below the healthy minimum of 5. It has decreased from 10.53 (Mar 23) to -53.22, marking a decrease of 63.75.
For Cash EPS (Rs.), as of Mar 24, the value is -30.18. This value is below the healthy minimum of 3. It has decreased from 35.04 (Mar 23) to -30.18, marking a decrease of 65.22.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 278.09. It has decreased from 348.70 (Mar 23) to 278.09, marking a decrease of 70.61.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 278.09. It has decreased from 348.70 (Mar 23) to 278.09, marking a decrease of 70.61.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 418.62. It has decreased from 460.36 (Mar 23) to 418.62, marking a decrease of 41.74.
For PBDIT / Share (Rs.), as of Mar 24, the value is 72.13. This value is within the healthy range. It has decreased from 91.97 (Mar 23) to 72.13, marking a decrease of 19.84.
For PBIT / Share (Rs.), as of Mar 24, the value is 51.50. This value is within the healthy range. It has decreased from 70.31 (Mar 23) to 51.50, marking a decrease of 18.81.
For PBT / Share (Rs.), as of Mar 24, the value is 1.29. This value is within the healthy range. It has decreased from 30.78 (Mar 23) to 1.29, marking a decrease of 29.49.
For Net Profit / Share (Rs.), as of Mar 24, the value is -50.80. This value is below the healthy minimum of 2. It has decreased from 13.37 (Mar 23) to -50.80, marking a decrease of 64.17.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -53.21. This value is below the healthy minimum of 2. It has decreased from 10.53 (Mar 23) to -53.21, marking a decrease of 63.74.
For PBDIT Margin (%), as of Mar 24, the value is 17.22. This value is within the healthy range. It has decreased from 19.97 (Mar 23) to 17.22, marking a decrease of 2.75.
For PBIT Margin (%), as of Mar 24, the value is 12.30. This value is within the healthy range. It has decreased from 15.27 (Mar 23) to 12.30, marking a decrease of 2.97.
For PBT Margin (%), as of Mar 24, the value is 0.30. This value is below the healthy minimum of 10. It has decreased from 6.68 (Mar 23) to 0.30, marking a decrease of 6.38.
For Net Profit Margin (%), as of Mar 24, the value is -12.13. This value is below the healthy minimum of 5. It has decreased from 2.90 (Mar 23) to -12.13, marking a decrease of 15.03.
For NP After MI And SOA Margin (%), as of Mar 24, the value is -12.71. This value is below the healthy minimum of 8. It has decreased from 2.28 (Mar 23) to -12.71, marking a decrease of 14.99.
For Return on Networth / Equity (%), as of Mar 24, the value is -19.13. This value is below the healthy minimum of 15. It has decreased from 3.13 (Mar 23) to -19.13, marking a decrease of 22.26.
For Return on Capital Employeed (%), as of Mar 24, the value is 17.01. This value is within the healthy range. It has increased from 13.84 (Mar 23) to 17.01, marking an increase of 3.17.
For Return On Assets (%), as of Mar 24, the value is -10.45. This value is below the healthy minimum of 5. It has decreased from 1.53 (Mar 23) to -10.45, marking a decrease of 11.98.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.40 (Mar 23) to 0.00, marking a decrease of 0.40.
For Total Debt / Equity (X), as of Mar 24, the value is 0.12. This value is within the healthy range. It has decreased from 0.45 (Mar 23) to 0.12, marking a decrease of 0.33.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.70. It has decreased from 0.71 (Mar 23) to 0.70, marking a decrease of 0.01.
For Current Ratio (X), as of Mar 24, the value is 1.28. This value is below the healthy minimum of 1.5. It has decreased from 1.96 (Mar 23) to 1.28, marking a decrease of 0.68.
For Quick Ratio (X), as of Mar 24, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.37 (Mar 23) to 0.84, marking a decrease of 0.53.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.15. This value is below the healthy minimum of 4. It has decreased from 1.31 (Mar 23) to 1.15, marking a decrease of 0.16.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is -4.69. This value is below the healthy minimum of 20. It has decreased from 23.73 (Mar 23) to -4.69, marking a decrease of 28.42.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is -7.66. This value is below the healthy minimum of 20. It has decreased from 7.76 (Mar 23) to -7.66, marking a decrease of 15.42.
For Earning Retention Ratio (%), as of Mar 24, the value is 104.69. This value exceeds the healthy maximum of 70. It has increased from 76.27 (Mar 23) to 104.69, marking an increase of 28.42.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 107.66. This value exceeds the healthy maximum of 70. It has increased from 92.24 (Mar 23) to 107.66, marking an increase of 15.42.
For Interest Coverage Ratio (X), as of Mar 24, the value is 3.94. This value is within the healthy range. It has decreased from 7.42 (Mar 23) to 3.94, marking a decrease of 3.48.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -0.80. This value is below the healthy minimum of 3. It has decreased from 4.27 (Mar 23) to -0.80, marking a decrease of 5.07.
For Enterprise Value (Cr.), as of Mar 24, the value is 26,350.45. It has increased from 16,364.27 (Mar 23) to 26,350.45, marking an increase of 9,986.18.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.23. This value is within the healthy range. It has increased from 1.26 (Mar 23) to 2.23, marking an increase of 0.97.
For EV / EBITDA (X), as of Mar 24, the value is 12.95. This value is within the healthy range. It has increased from 6.31 (Mar 23) to 12.95, marking an increase of 6.64.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.29. This value is within the healthy range. It has increased from 1.01 (Mar 23) to 2.29, marking an increase of 1.28.
For Retention Ratios (%), as of Mar 24, the value is 104.69. This value exceeds the healthy maximum of 70. It has increased from 76.26 (Mar 23) to 104.69, marking an increase of 28.43.
For Price / BV (X), as of Mar 24, the value is 3.44. This value exceeds the healthy maximum of 3. It has increased from 1.38 (Mar 23) to 3.44, marking an increase of 2.06.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.29. This value is within the healthy range. It has increased from 1.01 (Mar 23) to 2.29, marking an increase of 1.28.
For EarningsYield, as of Mar 24, the value is -0.05. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to -0.05, marking a decrease of 0.07.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Glenmark Pharmaceuticals Ltd as of February 27, 2025 is: ₹1,829.76

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 27, 2025, Glenmark Pharmaceuticals Ltd is Undervalued by 40.21% compared to the current share price 1,305.00

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Glenmark Pharmaceuticals Ltd as of February 27, 2025 is: 758.23

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 27, 2025, Glenmark Pharmaceuticals Ltd is Overvalued by 41.90% compared to the current share price ₹1,305.00

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -58.56%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 15.50%, which is a positive sign. The company has higher reserves (5,695.69 cr) compared to borrowings (3,769.15 cr), indicating strong financial stability. The company has shown consistent growth in sales (9.08 cr) and profit (299.85 cr) over the years.	The stock has a high average Working Capital Days of 92.33, which may not be favorable. The stock has a high average Cash Conversion Cycle of 85.33, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glenmark Pharmaceuticals Ltd:
1. Net Profit Margin: -12.13%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 17.01% (Industry Average ROCE: 16.18%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -19.13% (Industry Average ROE: 16.43%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): -0.8
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.84
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 0 (Industry average Stock P/E: 41.61)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.12
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 7891.12 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai Maharashtra 400026	complianceofficer@glenmarkpharma.com http://www.glenmarkpharma.com

Management
Name	Position Held
Mr. Glenn Saldanha	Chairman & Managing Director
Mrs. Cherylann Pinto	Executive Director - Corporate Affairs
Mr. V S Mani	Executive Director & Global CFO
Mrs. B E Saldanha	Non Executive Director
Ms. Saira Ramasastry	Ind. Non-Executive Director
Mrs. Vijayalakshmi Iyer	Ind. Non-Executive Director
Mr. Rajesh V Desai	Ind. Non-Executive Director
Mr. Dipankar Bhattacharjee	Ind. Non-Executive Director

FAQ

What is the latest intrinsic value of Glenmark Pharmaceuticals Ltd?

Let's break down Glenmark Pharmaceuticals Ltd's intrinsic value simply:

We calculate intrinsic value using the PE Ratio Method - comparing the company's current price-to-earnings ratio with its historical average and industry peers. Think of it like checking if a stock is "on sale" compared to its typical pricing.

As of 27 February 2025:

Calculated Fair Value: ₹1829.76
Current Market Price: ₹1,305.00
Variance: 40.21% higher

This suggests Glenmark Pharmaceuticals Ltd is currently undervalued by 40.21%. For context:

Market Cap: 36,826 Cr.
52-Week Range: 1,831/883
Reserves (Sep 2024): 8,417 Cr
Liabilities: 15,165 Cr

Remember: The PE method gives a snapshot based on earnings multiples. While useful for quick comparisons, investors should also consider growth prospects, industry trends, and economic conditions. This calculation assumes historical PE ratios remain relevant - always verify with current market dynamics.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

The Market Cap of Glenmark Pharmaceuticals Ltd is 36,826 Cr..

What is the current Stock Price of Glenmark Pharmaceuticals Ltd as on 27 February 2025?

The current stock price of Glenmark Pharmaceuticals Ltd as on 27 February 2025 is ₹1,305.

What is the High / Low of Glenmark Pharmaceuticals Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Glenmark Pharmaceuticals Ltd stocks is 1,831/883.

What is the Stock P/E of Glenmark Pharmaceuticals Ltd?

The Stock P/E of Glenmark Pharmaceuticals Ltd is .

What is the Book Value of Glenmark Pharmaceuticals Ltd?

The Book Value of Glenmark Pharmaceuticals Ltd is 299.

What is the Dividend Yield of Glenmark Pharmaceuticals Ltd?

The Dividend Yield of Glenmark Pharmaceuticals Ltd is 0.19 %.

What is the ROCE of Glenmark Pharmaceuticals Ltd?

The ROCE of Glenmark Pharmaceuticals Ltd is 12.3 %.

What is the ROE of Glenmark Pharmaceuticals Ltd?

The ROE of Glenmark Pharmaceuticals Ltd is 50.9 %.

What is the Face Value of Glenmark Pharmaceuticals Ltd?

The Face Value of Glenmark Pharmaceuticals Ltd is 1.00.